Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 2, 2014
[Denosumab for bone metastasis of thoracic tumors-preparation of a practice manual and evaluation of its effectiveness]Yoko Kondo, Motohiro Tamiya, Tomonori Hirashima, et al.
Cancer Chemotherapy and Pharmacology|July 9, 2017
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 studyTakayuki Shiroyama, Motohiro Tamiya, Seigo Minami, et al.
Cancer Genetics|June 15, 2021
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitorsKei Kunimasa, Yosuke Hirotsu, Yoji Kukita, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|September 22, 2009
[The contribution of widely used devices in the diagnosis of peripheral pulmonary lesions in patients presenting with respiratory distress]Motohiro Tamiya, Shinji Sasada, Nobuko Uehara, et al.
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Lung Cancer (Amsterdam, Netherlands)|December 5, 2020
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunctionKei Kunimasa, Toru Oka, Satoshi Hara, et al.
Cancer Science|October 27, 2021
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019LShinya Sakata, Kohei Otsubo, Hisako Yoshida, et al.
Clinical and Translational Radiation Oncology|September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort studyYuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Investigational New Drugs|August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs|January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 2, 2014
[Denosumab for bone metastasis of thoracic tumors-preparation of a practice manual and evaluation of its effectiveness]Yoko Kondo, Motohiro Tamiya, Tomonori Hirashima, et al.
Cancer Chemotherapy and Pharmacology|July 9, 2017
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 studyTakayuki Shiroyama, Motohiro Tamiya, Seigo Minami, et al.
Cancer Genetics|June 15, 2021
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitorsKei Kunimasa, Yosuke Hirotsu, Yoji Kukita, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|September 22, 2009
[The contribution of widely used devices in the diagnosis of peripheral pulmonary lesions in patients presenting with respiratory distress]Motohiro Tamiya, Shinji Sasada, Nobuko Uehara, et al.
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Lung Cancer (Amsterdam, Netherlands)|December 5, 2020
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunctionKei Kunimasa, Toru Oka, Satoshi Hara, et al.
Cancer Science|October 27, 2021
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019LShinya Sakata, Kohei Otsubo, Hisako Yoshida, et al.
Clinical and Translational Radiation Oncology|September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort studyYuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Investigational New Drugs|August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs|January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Pageof 20